BioCryst Pharmaceuticals, Inc.  

(Public, NASDAQ:BCRX)   Watch this stock  
6.41
+0.08 (1.26%)
After Hours: 6.41 0.00 (0.00%)
Apr 27, 4:43PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.25 - 6.53
52 week 2.49 - 9.25
Open 6.38
Vol / Avg. 1.05M/977,290.00
Mkt cap 502.52M
P/E     -
Div/yield     -
EPS -0.75
Shares 80.38M
Beta 3.45
Inst. own 73%
May 24, 2017
BioCryst Pharmaceuticals Inc Annual Shareholders Meeting - 11:00AM EDT - Add to calendar
May 4, 2017
Q1 2017 BioCryst Pharmaceuticals Inc Earnings Call - 11:00AM EDT - Add to calendar
May 4, 2017
Q1 2017 BioCryst Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Apr 4, 2017
BioCryst Pharmaceuticals Inc at Needham Healthcare Conference - Webcast
Mar 14, 2017
BioCryst Pharmaceuticals Inc at Barclays Global Healthcare Conference
Feb 27, 2017
Q4 2016 BioCryst Pharmaceuticals Inc Earnings Release
Feb 27, 2017
Q4 2016 BioCryst Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -50.13% -209.25%
Operating margin -91.15% -184.45%
EBITD margin - -182.61%
Return on average assets -19.92% -51.97%
Return on average equity -648.41% -223.70%
Employees 65 -
CDP Score - -

Address

4505 Emperor Blvd Ste 200
DURHAM, NC 27703-8457
United States - Map
+1-919-8591302 (Phone)
+1-919-8591314 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Officers and directors

Jon P. Stonehouse President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Thomas R. Staab II Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
Age: 70
Bio & Compensation  - Reuters
Yarlagadda S. Babu Ph.D. Senior Vice President - Drug Discovery
Age: 62
Bio & Compensation  - Reuters
Lynne Powell Senior Vice President, Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
William P. Sheridan Senior Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Alane P. Barnes Vice President, General Counsel, and Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
George B. Abercrombie Non-Executive Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D., M.D. Director
Age: 59
Bio & Compensation  - Reuters
Robert A. Ingram Director
Age: 73
Bio & Compensation  - Reuters
Sanj K. Patel Director
Age: 46
Bio & Compensation  - Reuters